BR0306732A - Tratamentos em combinação para doença alérgica compreendendo a administração de um anticorpo anti-ige e composto antialérgico - Google Patents

Tratamentos em combinação para doença alérgica compreendendo a administração de um anticorpo anti-ige e composto antialérgico

Info

Publication number
BR0306732A
BR0306732A BR0306732-7A BR0306732A BR0306732A BR 0306732 A BR0306732 A BR 0306732A BR 0306732 A BR0306732 A BR 0306732A BR 0306732 A BR0306732 A BR 0306732A
Authority
BR
Brazil
Prior art keywords
ige antibody
allergic disease
combination treatments
administering
compound
Prior art date
Application number
BR0306732-7A
Other languages
English (en)
Inventor
Charles Edward Owen
Howard Fox
Christoph Walker
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0306732A publication Critical patent/BR0306732A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"TRATAMENTOS EM COMBINAçãO PARA DOENçA ALéRGICA COMPREENDENDO A ADMINISTRAçãO DE UM ANTI-CORPO ANTI-IGE E COMPOSTO ANTIALéRGICO". A presente invenção refere-se a composição farmacêutica que compreende um anticorpo anti-IgE e pelo menos um outro composto antialérgico selecionado dentre o grupo consistindo em agentes antiinflamatórios, modificadores de leucotrieno, broncodilatadores, anti-histaminas, antagonistas de interleucina, inibidores de mastócitos, e agentes imunoterapêuticos, como 33-epicloro,33-desoxiascomicina (pimecrolimus), em que os ingredientes ativos estão presentes na forma livre ou na forma de um sal farmaceuticamente aceitável ou opcionalmente pelo menos um veículo farmaceuticamente aceitável para uso simultâneo, separado ou seq³encial.
BR0306732-7A 2002-01-09 2003-01-09 Tratamentos em combinação para doença alérgica compreendendo a administração de um anticorpo anti-ige e composto antialérgico BR0306732A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0200429.9A GB0200429D0 (en) 2002-01-09 2002-01-09 Organic compounds
PCT/EP2003/000154 WO2003057249A1 (en) 2002-01-09 2003-01-09 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound

Publications (1)

Publication Number Publication Date
BR0306732A true BR0306732A (pt) 2004-12-28

Family

ID=9928810

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0306732-7A BR0306732A (pt) 2002-01-09 2003-01-09 Tratamentos em combinação para doença alérgica compreendendo a administração de um anticorpo anti-ige e composto antialérgico

Country Status (9)

Country Link
US (2) US20050042215A1 (pt)
EP (1) EP1465662A1 (pt)
JP (1) JP2005514414A (pt)
CN (1) CN1612751A (pt)
AU (1) AU2003210153A1 (pt)
BR (1) BR0306732A (pt)
CA (1) CA2472151A1 (pt)
GB (1) GB0200429D0 (pt)
WO (1) WO2003057249A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0209474A (pt) * 2001-05-09 2006-02-07 Novartis Ag Métodos para imunomodulação seletiva
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
CA2539324A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
WO2005030331A1 (en) * 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Combination antihistamine medication
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
GB0502358D0 (en) * 2005-02-04 2005-03-16 Novartis Ag Organic compounds
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US8637070B2 (en) * 2005-02-09 2014-01-28 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
EP2001438A2 (en) 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
JP2010519194A (ja) * 2007-02-15 2010-06-03 アストラゼネカ・アクチエボラーグ ＩｇＥ分子に対する結合要素
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
AU2019244666A1 (en) * 2018-03-26 2020-10-08 Novartis Ag Methods of treating chronic spontaneous urticaria using ligelizumab
CN114504644B (zh) * 2021-12-24 2024-02-13 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
JP2003524602A (ja) * 1998-09-18 2003-08-19 ダイナバックス テクノロジーズ コーポレイション ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物
GB0012383D0 (en) * 2000-05-22 2000-07-12 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
GB0200429D0 (en) 2002-02-27
US20050042215A1 (en) 2005-02-24
CA2472151A1 (en) 2003-07-17
WO2003057249A1 (en) 2003-07-17
EP1465662A1 (en) 2004-10-13
US20060240000A1 (en) 2006-10-26
AU2003210153A1 (en) 2003-07-24
CN1612751A (zh) 2005-05-04
JP2005514414A (ja) 2005-05-19

Similar Documents

Publication Publication Date Title
BR0306732A (pt) Tratamentos em combinação para doença alérgica compreendendo a administração de um anticorpo anti-ige e composto antialérgico
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
WO2005070126A3 (en) Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
BRPI0607349A2 (pt) combinação de xolair com agente imunossupressor
BR0317524A (pt) Compostos derivados de pirrolopirimidina, composição farmacêutica, processo para as suas preparações e respectivo uso
BRPI0411241A (pt) agentes terapêuticos úteis para o tratamento de dor
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
AR085778A2 (es) Forma de dosis solida enterica revestida, que comprende acido micofenolico o sal micofenolato
CA2440111A1 (en) Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
DE60021570D1 (de) Neue zubereitung und darreichungsform enthaltend einen säurelabilen protonenpumpeninhibitor
WO2005107801A3 (en) Systems and methods for treating human inflammatory and proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors and/or ucp and/or fas antibodies
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
EA200400664A1 (ru) Фармацевтические композиции, включающие метформин и глибенкламид, применяемые для лечения сахарного диабета типа ii
BRPI0411165A (pt) composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso
BR0316305A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, métodos para tratar a dor em um animal, para estimular a função do receptor opióide em uma célula, para preparar uma composição, e para tratar diarréia em um animal, composição, e kit
BRPI0513944A (pt) forma substancialmente pura de um composto de quinazolina, uso de um composto de quinazolina e composição
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
TR199802769T2 (xx) Terpenoid bileşikler ile antihistaminik bileşiklerin bir kombinasyonunu ihtiva eden topikal bileşim.
ATE287267T1 (de) Kombinationstherapien mit gefässschädigender aktivität
AR026197A1 (es) Uso de dipiridamol o mopidamol para el tratamiento y prevencion de trastornos de la microcirculacion dependientes de fibrina
BRPI0409878A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
ATE390124T1 (de) Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin
AR050574A1 (es) Uso de un compuesto para estimulacion del crecimiento de pelo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A(S) 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.